

Kluwer Patent Blog

Merck Sharp & Dohme / Sandoz, Court of Appeal The Hague (Gerechtshof Den Haag), 1 May 2012

Peter Burgers (Brinkhof) · Tuesday, June 19th, 2012

The Court of Appeal confirms the revocation by the District Court of a patent relating to a coformulation of timolol and dorzolamide for the treatment of glaucoma, for lack of inventive step. The combination of these two substances was disclosed before the priority date as a concomitant therapy. The skilled person would turn this concomitant therapy into a topical coformulation in order to increase therapy compliance, which is a known problem in the treatment of glaucoma.

Click [here](#) for the full text of this case.

A summary of this case will be posted on <http://www.KluwerIPCases.com>

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe [here](#).

Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.


79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



Wolters Kluwer



2022 SURVEY REPORT
The Wolters Kluwer Future Ready Lawyer
Leading change

This entry was posted on Tuesday, June 19th, 2012 at 3:24 pm and is filed under [Case Law](#), [Chemical Engineering](#), [Inventive step](#), [Netherlands](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.